Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
10 mars 2022 09h00 HE
|
Progenity, Inc.
Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery A Clinical Device Performance Study in Patients with Ulcerative Colitis is Now Recruiting SAN...
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
28 févr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
22 févr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
16 févr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
25 janv. 2022 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
11 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
05 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
03 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
20 déc. 2021 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces New Patent for Single-Molecule Detection Technology
02 déc. 2021 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...